DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
Karolina CyllErik Skaaheim HaugManohar PradhanLjiljana VlatkovicBirgitte CarlsenSven LöffelerWanja KildalKarin SkogstadFrida Hauge TorkelsenRolf Anders SyvertsenHanne A AskautrudKnut LiestølAndreas KleppeHåvard E DanielsenPublished in: British journal of cancer (2024)
DNA ploidy and PTEN could serve as additional biomarkers to identify AS patients at increased risk of developing aggressive disease, enabling earlier intervention for nearly 50% of the patients that will eventually receive treatment with current protocol.
Keyphrases
- end stage renal disease
- randomized controlled trial
- circulating tumor
- prostate cancer
- cell proliferation
- ejection fraction
- cell free
- chronic kidney disease
- newly diagnosed
- single molecule
- pi k akt
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- nucleic acid
- signaling pathway
- benign prostatic hyperplasia
- combination therapy
- replacement therapy
- smoking cessation